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Staging laparotomy (SL) was introduced into the
management of patients with Hodgkin's disease in
about 1959 as a means of detecting occult intra-
abdominal disease, and in recent years its role has
diminished and become more clearly defined. (Glees
et al., 1982) Some patients with non-Hodgkin's
lymphoma (NHL), but only a minority, have been
staged in this way also, the personal series reported
here probably being the largest in this country. SL
will indeed detect occult intra-abdominal disease in
patients with apparently localised NHL, converting
in the order of 10-30% of patients from clinical
stage (CS) I or II to pathological stage (PS) III or
IV. (Veronesi et al., 1974; Kim & Dorfman, 1974;
Bitran et al., 1977; Goffinet et al., 1977; Heifetz et
al., 1980; Toonkel et al., 1980). It became apparent
in the late 1970s, however, that the use of SL in
patients with NHL in an analogous fashion to its
use in Hodgkin's disease was inappropriate. The
published results of SL from Stanford and from
other centres indicated that SL was of limited value
in view of the frequently disseminated nature of the
disease at presentation, the success of less invasive
staging techniques in detecting systemic
involvement, and the failure of non-systemic
therapy to prevent early relapse. (Dick et al., 1974;
Fraser et al., 1979; Ribas-Mundo & Rosenberg,
1979; Horwich & Peckham, 1983). The purpose of
this paper is to re-evaluate SL in patients with
NHL according to other criteria, viz. the pattern of
relapse and survival after a minimum of 5 years
follow-up, in order to determine whether or not any
subgroup can be identified for whom SL might be
justified.
Fifty patients with NHL undergoing SL under
the care of one surgeon (J-CG) between 1969 and
1978 have been followed up for a minimum of 5
years. Thirty-three patients presented with nodal
disease and 4 with extranodal disease (tonsil, testis,
skin and parotid) and underwent SL in an
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analogous fashion to patients with Hodgkin's
disease. The diagnosis had been established by
biopsy of an appropriate site, and full staging
investigations including bipedal lymphography,
bone marrow biopsy, liver biopsy and sometimes
CAT scanning or lumbar puncture had been
performed. The laparotomy protocol was essentially
the same as for Hodgkin's disease with
splenectomy, wedge liver biopsy and multiple node
biopsies particularly of mesenteric nodes. Thirteen
patients presented with abdominal disease. For 7 of
these patients laparotomy was a diagnostic as well
as a staging procedure, as the suspected diagnosis
of lymphoma had not been confirmed
histologically. For the other 6 patients, SL was a
"second look" staging procedure, as the diagnosis
of abdominal lymphoma had already been made at
a referring hospital. Splenectomy and liver biopsy
were performed in addition to re-assessing the sites
of disease determined at the original laparotomy, in
order to determine whether further local or
systemic therapy was appropriate.
The pathological versus clinical staging of the 50
patients is shown in Table I. A total of 9 patients
were "upstaged" by SL, 7 to PS IV by virtue of
liver involvement or positive iliac crest bone biopsy.
No patients were "downstaged" by SL. This yield
of positive findings is similar to that reported in
other series. The 7 patients undergoing diagnostic/
staging laparotomies were found to have unresectable
Table I Clinical vs. pathological staging in 50
patients
Pathological staging
I II III IV
I 9 2
Clinical II 20 - 2
staging III 12 5
Clinical staging according to the Ann Arbor
criteria (Carbone et al., 1971). Pathological
staging refers to the staging assigned on the
basis of laparotomy findings.
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tumours, and biopsy alone was performed, con-
firming the suspected diagnosis of lymphoma. All
subsequently received chemotherapy, and the
staging procedures of splenectomy and liver biopsy
did not contribute to this decision. The 6 patients
undergoing "second look" SL had the diagnosis of
abdominal lymphoma established at referring
hospitals. Three had undergone "curative" resection
at the first laparotomy, and no residual tumour was
found at SL. The other 3 had been considered
unresectable; no further resection was possible at
SL in 2, and no residual tumour was found in the
third patient since he had received combination
chemotherapy following the first laparotomy.
"Second look" SL did not contribute to the
management of any of these patients.
The patients have been followed up for a
minimum of 5 years. Of the total 50 patients, 6
died within 3 months either as operative or
postoperative complications (3 cases), or of
extensive lymphoma (3 cases). Of the remaining 44
patients, 20 relapsed within 5 years and 13 of these
have died of their disease. The majority of relapses
occurred relatively soon after SL and initial
therapy, with 10 patients having relapsed within 6
months of SL and 16 patients within 2 years. The
sites of relapse are shown in Table II. Of the 20
patients who relapsed, 16 did so in extra-nodal
sites; liver, bone marrow, bone deposits, CNS,
breasts, lung, Waldeyer's ring.
Relapse rates correlated with pathological stage
(Table III). Patients with PS I disease did well, with
Table II Site and time ofrelapse
Clinical Pathological Time offirst Site of 5-year
staging staging relapse relapse follow-up
I A III A 18 months left neck died 2 years
I A III A 6 months bone deposits died 1 year
II A II A 3 years left neck disease free
II A II A 4 months tonsil/neck disease free
II A II A 9 months nasopharynx disease free
II E II E 6 months abdo nodes disease free
II E II E 5 years CNS died 6 years
II E IV 4 months liver died 6 month
II A IV 4 years abdo nodes disease free
III A III A 6 months bone marrow died 8 month
III A III A 6 months bone marrow died 1 year
III A III A 2 years CNS died 2 years
III A III A 4 years CNS died 4 years
III A III A 6 months lung disease free
III A III A 2 months breasts died 4 years
III B III B 1 year bone marrow died 2 years
III B III B 2 years bone marrow died 2 years
III B III B 2 years liver died 3 years
III B IV 3 months liver/marrow died 9 month
III B IV 3 months bone deposit died 1 year
Table III Five-year survival and pathological stage
Pathological No. of Death within 5-year relapse S-year
stage patients 3 months free survival survival
IA 4 1 3 3
IE 5 0 5 5
IIA 11 1 7 10
II E 9 1 6 8
III A 10 1 1 2
III B 4 0 1 1
IV 7 2 1 2
Total 50 6 24 31
Pathological stage "B" refers to the presence of "B symptoms",
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no relapses following radiotherapy. This may reflect
the selected nature of our pathologically staged
patients, as other series report a 5-year relapse free
survival of only 40-60% for CS I patients treated
with radiotherapy alone. (Jones et al., 1973;
Peckham et al., 1975; Hellman et al., 1977; Reddy
et al., 1977; Chen et al., 1979; Lester et al., 1982).
Even if our 11 CS I patients had not been
laparotomised, at least 8 would have been long
survivors. Patients with PS III or IV disease were
usually treated with combination chemotherapy and
involved field radiotherapy, and had a 5-year
relapse free survival of 3/21 patients (14%). Relapse
and survival also correlated with histological sub-
type, with higher relapse rates in patients with "bad
risk" lymphoma. (Rosenberg, 1979; Horwich &
Peckham, 1983). (Table IV). However, it was not
possible to predict which CS I patients would be
PS I and long survivors on the basis of histologi-
cal sub-type.
In conclusion, 5-year follow up of our series of
50 patients with NHL who underwent SL reveals
that only a small group have "benefited" from this
procedure; viz. the 7 patients who were clinically
and pathologically stage I whom SL correctly
defined as being curable by radiotherapy alone. For
the rest, SL was unable to predict who was at risk
of early relapse or of relapse with intra-abdominal
disease. The high incidence of relapse, particularly
in extranodal sites and occurring relatively quickly
after treatment indicates that the majority of
patients should have been regarded as having a
disseminated disease from the outset. SL had a
significant mortality and morbidity, even when
compared to the complications of combination
chemotherapy, and this outweighed any advantage
conferred on the minority of patients whom
laparotomy assigned to treatment with radiotherapy
alone. Our alternative policy of management for CS
I patients of local treatment alone, with
chemotherapy reserved for patients who relapse, is
highly effective; and indeed chemotherapy may be
used as the primary treatment modality in patients
with CS I disease. SL is not therefore recommended
for patients with NHL regardless of their clinical
stage.
When a "diagnostic" laparotomy for suspected
lymphoma is performed, or a lymphoma is found at
an emergency laparotomy for an intra-abdominal
complication, there is no virtue in performing a
splenectomy, but a liver biopsy and biopsy of
palpably abnormal nodes or mesenteric nodes is
recommended. The most useful staging procedure is
probably bone marrow biopsy from a number of
sites, and if this can be performed under general
anaesthesia at the time of laparotomy then the
patient will be grateful. "Second look" SL is not
justified as chemotherapy is usually the treatment
of choice for relapsed disease, and patients can be
adequately followed up using non-operative staging
techniques.
Table IV Five-year survival and histological typea
No. of 5-year relapse S-year
Histology patients free survival survival
Poorly diff. PDLN 10 4 5
lymphocytic nodular
Nodular histiocytic NH 1 0 1
Nodular mixed NMX 2 0 1
Well diff. WDLD 4 3 4
lymphocytic diffuse
Poorly diff. PDLD 13 6 7
lymphocytic diffuse
Diffuse mixed DMX 2 2 2
Diffuse histiocytic DH 18 9 11
Total 50 24 31
aRappaport (1966) classification.422 L.C. BARR et al.
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